The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

The Community Oncology Alliance said CMS’s final 2027 outpatient rule pays 340B hospitals ASP minus 28% for drugs, but physician payment cuts still threaten practices.

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer progression-free survival after retreatment.

The investigational alpha emitter 212Pb-VMT-α-NET yielded encouraging response rates in PRRT-naive SSTR2+ NETs.

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and dosimetry to alpha-emitting therapies.

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.

During a live event, Wade T. Iams, MD, discussed the issues facing oncologists selecting treatment for patients with extensive-stage small cell lung cancer.